Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

Lisa R. Forbes(Baylor College of Medicine), Jennifer W. Leiding(Johns Hopkins University), Helen C. Su(National Institute of Allergy and Infectious Diseases), Katja G. Weinacht(Stanford Medicine), Paul Szabolcs(Children's Hospital of Pittsburgh), Charlotte Cunningham‐Rundles(Icahn School of Medicine at Mount Sinai), Edith Schussler(Icahn School of Medicine at Mount Sinai), R. Paul Guillerman(Baylor College of Medicine), Tiphanie P. Vogel(Baylor College of Medicine), Eric J. Allenspach(University of Washington), Peter Olbrich(Instituto de Biomedicina de Sevilla), Johana B Castro-Wagner(University of South Florida St. Petersburg), Yeşim Yılmaz Demirdağ(Morgan Stanley Children's Hospital), Joshua D. Milner(National Institute of Allergy and Infectious Diseases), Megan A. Cooper(Washington University in St. Louis), Alexandra F. Freeman(National Institutes of Health), Ashley Plant(Children's Hospital of Orange County), Niraj Patel(Levine Children's Hospital), Troy R. Torgerson(Allen Institute for Immunology), Mary Slatter(First Pavlov State Medical University of St. Petersburg), Olive S. Eckstein(Children's Cancer Center), Christa S. Zerbe(National Institutes of Health), Mario Abinun(North Tyneside General Hospital), Desa Lilić(Newcastle University), Steven M. Holland(National Institute of Allergy and Infectious Diseases), Andrew R. Gennery(Newcastle upon Tyne Hospitals NHS Foundation Trust)
Journal of Allergy and Clinical Immunology
August 6, 2018
Cited by 261


Related Papers